Recursion Pharmaceuticals is the test case for whether AI-discovered drugs can actually clear clinical trials
Recursion Pharmaceuticals built its identity around a bet that biology could be industrialized the way chip design was: generate massive proprietary datasets of cellular imaging and genomic perturbation experiments, train machine learning models on that data to identify promising drug candidates and
Source: WSJ